MARKET

VYGR

VYGR

Voyager Therapeutics Inc
NASDAQ
3.990
+0.130
+3.37%
After Hours: 3.910 -0.08 -2.01% 18:51 04/01 EDT
OPEN
3.890
PREV CLOSE
3.860
HIGH
4.090
LOW
3.890
VOLUME
507.97K
TURNOVER
--
52 WEEK HIGH
5.55
52 WEEK LOW
2.645
MARKET CAP
237.80M
P/E (TTM)
-1.9561
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at VYGR last week (0323-0327)?
Weekly Report · 2d ago
Voyager Therapeutics: Early-Stage Tau Program Optionality Drives High-Risk, High-Upside Buy Rating
TipRanks · 03/23 23:35
Weekly Report: what happened at VYGR last week (0316-0320)?
Weekly Report · 03/23 09:57
Voyager Therapeutics Price Target Maintained With a $25.00/Share by HC Wainwright & Co.
Dow Jones · 03/17 17:41
HC Wainwright & Co. Reiterates Buy on Voyager Therapeutics, Maintains $25 Price Target
Benzinga · 03/17 17:35
Voyager Therapeutics: Differentiated CNS Platform, Strategic Partnerships, and 2026 Data Catalysts Underpin Buy Rating
TipRanks · 03/17 16:45
Analysts Offer Insights on Healthcare Companies: Merit Medical Systems (MMSI), Voyager Therapeutics (VYGR) and Structure Therapeutics, Inc. Sponsored ADR (GPCR)
TipRanks · 03/17 11:30
Weekly Report: what happened at VYGR last week (0309-0313)?
Weekly Report · 03/16 09:57
More
About VYGR
Voyager Therapeutics, Inc. is a biotechnology company engaged in leveraging the power of human genetics to modify the course of neurological diseases. The Company’s pipeline includes programs for Alzheimer’s disease, Friedreich’s ataxia, Parkinson’s disease, amyotrophic lateral sclerosis (ALS), and multiple other diseases of the central nervous system. Many of its programs are derived from its Tropism Redirection of AAV by Cell-type-specific Expression of RNA (TRACER) adeno-associated virus (AAV) capsid discovery platform, which is used to generate capsids and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous dosing. Its pipeline of programs includes Anti-Tau Antibody (VY7523), Tau Silencing Gene Therapy (VY1706), SOD1 Silencing Gene Therapy Program, Vectorized Anti-Amyloid Antibody Early Research Program, Friedreich’s Ataxia Program: VY-FXN01, GBA1 Gene Replacement Program, HD Program and others.

Webull offers Voyager Therapeutics Inc stock information, including NASDAQ: VYGR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VYGR stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading VYGR stock methods without spending real money on the virtual paper trading platform.